IMV Inc IMVIQ

That's it. Delay in data collecting.

[Breakthorough1]

"As of May 7, 2020, a total of 92 patients out of the planned 184 patients were enrolled across all five indications at 19 clinical sites in Canada and the US. The COVID-19 pandemic has impacted data collection and validation processes and IMV now anticipates reporting updated results from this study in the second half of 2020." https://www.businesswire.com/news/home/20200515005219/en/

[pp19888]

I am here for covid 19 vaccine development, other drugs development is just a cherry on the cake. Nice to hear that human trial is not delayed and it's on track for this summer and their preclinical mouse data is coming before end of the May and the way they mentioned that phase 1 starting in summer, preclinical data looks promising. Gl

[qwerty22]

Good early spot by you on the basket trial delay. On the cc Mostly frustration on the slowing pace of all the oncology programs. Ovarian mono - the focus now on durability really speaks to me about the fact that the ORR is just not good enough. Well not good enough to carry the program alone, honestly if the ORR was good enough they wouldn't be waiting for the durability data. dlbcl

[qwerty22]

correction - if the gov WASNT on-board as a partner then they wouldn't proceed.

[pp19888]

Once they receive the grant that will clear all the doubt 

[qwerty22]

I guess one other point on peer review is if as Fred hinted this data is potentially high impact then they could secure a good journal which would secure a lot more publicity. Lots of "ifs" there.

[pp19888]

IMV's PT raised by HC Wainwright to $13.00 USD buy rating. https://www.marketbeat.com/r/1414136 $IMV 

[pp19888]

Looks like very easy to manipulate on the way down due to very little volume. This more looks like Double or triple  on next significant news release till then just ignore the price movement of sp. I got more shares than total number of shares traded today, so even if I sell at market it would see 2 buck or even less. Gl

[qwerty22]

One more thought. A lot of the questions on oncology from the analysts were about the path forward in the two lead programs. This is the big question for the next 6-12 months. Are we moving to a registrational trial or back to another exploratory trial? The company don't have any clear answers for that today. Those issues that still exist seem to potentially block just a straightforward move

[pp19888]

I think it's hold until the end of the year to get your question answers but I highly doubt if you can get the shares at current price.

[casher]

I don't remember last time this stock actually closed up on news... management still has a lot of work to do to earn back investor confidence. Personally would be good to shake up managment and get someone new in there Only postive sign about an entry at this point is that they are cashed up. Fingers crossed that $30 million dollars can actually create some value  GLTA

[pp19888]

Again, I am personally invested here just due to covid 19 vaccine development, I don't care about their other drug development plans. So far their preclinical work going as planned and human trial in summer, may get funding or grants from Canadian gov if early results are promising. Gl

[qwerty22]

I do care about the cancer programs but I also agree with you. Short/medium term Covid is the most likely source of increasing value. Can't see huge amount of movement on the cancer front before late-2020 if we are lucky (more likely 2021). Everything changes if they can get a cancer registrational trial going but if they can't explain a simple path to that to the analyst now then I don